Clinical Report: Integrative Analysis of SNRPA Overexpression in HCC Cells

Overview

This study identifies the role of SNRPA overexpression in transcriptomic and splicing changes in hepatocellular carcinoma (HCC) cells. The findings reveal significant alterations in gene expression and splicing events that may contribute to HCC progression.

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, characterized by rapid progression and limited treatment options. RNA-binding proteins (RBPs) have emerged as crucial regulators in HCC, influencing post-transcriptional gene regulation and tumorigenesis. Understanding the mechanisms by which RBPs like SNRPA affect HCC could provide insights into potential therapeutic targets.

Data Highlights

Key Findings

• SNRPA overexpression leads to significant transcriptomic changes in HCC cells.
• A total of 498 differentially expressed genes (DEGs) were identified.
• 2316 alternative splicing events (RASEs) were associated with SNRPA overexpression.
• 12 RNA-binding proteins known to be involved in HCC were modulated by SNRPA.
• Functional annotation revealed enrichment in pathways related to RNA processing and cell division.

Clinical Implications

The findings suggest that targeting SNRPA and its regulatory pathways may offer new therapeutic strategies for HCC. Understanding the role of SNRPA in gene expression and splicing could enhance the development of personalized treatment approaches.

Conclusion

SNRPA overexpression is linked to significant transcriptomic and splicing alterations in HCC, highlighting its potential role in cancer progression and the need for further functional studies.

References

1. EASL Clinical Practice Guidelines, ScienceDirect, 2025 -- Management of Hepatocellular Carcinoma
2. FDA, FDA, 2025 -- Approval of Nivolumab with Ipilimumab for HCC
3. RNA splicing dysregulation in hepatocellular carcinoma, ScienceDirect, 2026 -- Molecular mechanisms and therapeutic targets
4. Blood Cancer Journal — Discovery of Disease-Associated Aberrantly Spliced RNA Transcripts in Myeloma and Approaches for Targeting These Changes with RNA-Based Therapies
5. Blood Cancer Journal — Comprehensive Examination of Alternative Splicing Dynamics in Multiple Myeloma and the Implications of Altered Splicing Factors
6. Basic Research in Cardiology — Decreased A-to-I RNA Editing in the Failing Human Heart Influences Circular RNA Formation
7. the pathologist — Decoding RNA Expression in Cancer Data
8. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma - ScienceDirect
9. FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma | FDA
10. RNA splicing dysregulation in hepatocellular carcinoma: Molecular mechanisms, therapeutic targets, and intervention strategies—A comprehensive review - ScienceDirect